Finoriq research workspace
Xenon Pharmaceuticals Inc. (XENE) SEC Filings & Filing Highlights
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the. Review XENE SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
- Company
- Xenon Pharmaceuticals Inc. (XENE)
- Ticker
- XENE
- Market Cap
- $6.4B
- Latest Price
- $66.56
- Industry
- Biotech & Pharma
Xenon Pharmaceuticals Inc. (XENE) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Xenon Pharmaceuticals Inc. (XENE).
| Event | Form | Date |
|---|---|---|
| Xenon Pharmaceuticals Inc.: Shareholder voteAt the Annual Meeting, 90,399,636.29 of the Company’s common shares, or approximately 93.54% of the total common shares entitled to vote, w... | 8-K5.07 | 2026-06-03 |
| As discussed in Item 5.07 below, upon the recommendation of the Board of Directors (the “Board”...As discussed in Item 5.07 below, upon the recommendation of the Board of Directors (the “Board”) of Xenon Pharmaceuticals Inc. (the “Compan... | 8-K5.02 | 2026-06-03 |
| Xenon Reports Q1 2026 Financial Results and Provides Business UpdateXenon Reports Q1 2026 Financial Results and Provides Business Update | 8-K7.01 | 2026-05-07 |
| Xenon Reports Q1 2026 Financial Results and Provides Business UpdateXenon Reports Q1 2026 Financial Results and Provides Business Update | 8-K2.02 | 2026-05-07 |
| On April 7, 2026, Xenon Pharmaceuticals Inc. (the “Company”) amended and restated the Company’s...On April 7, 2026, Xenon Pharmaceuticals Inc. (the “Company”) amended and restated the Company’s Amended and Restated 2025 Inducement Equity... | 8-K5.02 | 2026-04-13 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.